<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695172</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00100742</org_study_id>
    <nct_id>NCT03695172</nct_id>
  </id_info>
  <brief_title>Comparison of TAP, Anterior QL, or ESP Block for Elective Cesarean Section</brief_title>
  <official_title>Comparison of TAP, Anterior QL, or ESP Block for Elective Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective single center, randomized study is to determine if ultrasound
      guided Transversus Abdominis Plane (TAP), Quadratus Lumborum (QL), and Erector Spinae Plane
      (ESP) blocks decrease opioid consumption in subjects undergoing elective cesarean section.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The typical anesthetic for cesarean section at Duke University Hospital includes a spinal or
      combined spinal epidural anesthetic with intrathecal dosing of 1.4-1.6 mL bupivacaine HCl
      0.75%, 15 mcg fentanyl, and 150 mcg morphine. If the epidural component of a combined spinal
      epidural anesthetic is used, the subject will be withdrawn from the study. Patients also
      receive rectal acetaminophen 975 mg prior to incision; intravenous (IV) ondansetron 4 mg, IV
      metoclopramide 10 mg, IV famotidine 20 mg and IV dexamethasone 4 mg intraoperatively; and IV
      ketorolac 15 mg prior to skin closure. There will be no change to this typical practice.

      Patients who consent to be in this study will be randomized to receive one of three truncal
      nerve blocks using an online randomization program by the study PI (AK/EG): (1)
      ultrasound-guided bilateral classic TAP block; (2) ultrasound-guided bilateral anterior QL
      (also known as transmuscular or QL type 3) block; (3) ultrasound-guided bilateral ESP block
      at the level of T9. These nerve blocks will be performed after delivery and within one hour
      of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side. Nerve
      blocks will be performed by a dedicated and trained group of regional anesthesiologists. This
      non-blinded regional anesthesiologist will save an ultrasound image after local anesthetic
      administration while the needle is still in position on each side. The study team will review
      these images to ensure a high quality of block performance.

      Patients will have standard postoperative pain medication orders, including acetaminophen 975
      mg PO Q6H for 4 days (scheduled, starting 6 hours after intraoperative rectal dose),
      ketorolac 15 mg IV Q6H for 24 hours (scheduled, starting 6 hours after intraoperative dose),
      ibuprofen 600 mg PO Q6H for 3 days (scheduled, starting 24 hours after first dose of
      ketorolac) and oxycodone 5-10mg PO Q3-4H PRN for 4 days. If patients are unable to tolerate
      oral medication or oxycodone is insufficient, rescue medications may be ordered: IV morphine
      1-2 mg or IV hydromorphone 0.3-0.5 mg Q4H as needed. There is no change from the standard
      postoperative order sets used for patients after cesarean section.

      Subjects' verbal pain scores at rest and with movement as well as opioid consumption will be
      recorded at 2, 6, 24, and 48 hours postoperatively. Additionally, the amount of antiemetics
      and antipruritics used will also be recorded at the above time points. These scores will be
      entered into a Duke University Hospital REDCap database. Subjects will also be sent a survey
      assessing their satisfaction with pain control one week after discharge via email or
      telephone. This information will be collected via Duke University Hospital REDCap.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Suspended due to COVID-19
  </why_stopped>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Anticipated">August 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly assigned to one of three treatment groups, TAP, QL, or ESP blocks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <description>Amount of opioid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Amount of opioid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Amount of opioid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>Amount of opioid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain scores</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <description>VAS pain scores at rest and with movement 0-10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain scores</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>VAS pain scores at rest and with movement 0-10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain scores</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>VAS pain scores at rest and with movement 0-10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain scores</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>VAS pain scores at rest and with movement 0-10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of antipruritics</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <description>Amount of antipruritics required by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of antipruritics</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Amount of antipruritics required by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of antipruritics</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Amount of antipruritics required by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of antipruritics</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>Amount of antipruritics required by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of antiemetics</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <description>Amount of antiemetics required by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of antiemetics</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Amount of antiemetics required by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of antiemetics</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Amount of antiemetics required by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of antiemetics</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>Amount of antiemetics required by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall satisfaction with pain control</measure>
    <time_frame>1 week postoperatively</time_frame>
    <description>Rate overall satisfaction from 0-10</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>TAP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QL block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine</description>
    <arm_group_label>ESP block</arm_group_label>
    <arm_group_label>QL block</arm_group_label>
    <arm_group_label>TAP block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAP block</intervention_name>
    <description>Patient will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.</description>
    <arm_group_label>TAP block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QL block</intervention_name>
    <description>Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.</description>
    <arm_group_label>QL block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ESP block</intervention_name>
    <description>Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% of ropivacaine with epinephrine 1:400,000 per side.</description>
    <arm_group_label>ESP block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. American Society of Anesthesiologists (ASA) Physical Status 1-3

          2. Age greater than or equal to 18 years

          3. Scheduled for elective cesarean section

          4. English speaking

        Exclusion Criteria:

          1. ASA Physical Status 4-5

          2. Diagnosis of chronic pain

          3. Chronic opioid use (opioid use in the past 3 months)

          4. Preoperative use of SSRIs (Celexa, Lexapro, Prozac, Paxil), SNRIs (Cymbalta, Effexor),
             gabapentin, or pregabalin (Lyrica)

          5. Inability to cooperate with or understand protocol

          6. Inability to communicate pain scores or need for analgesia

          7. Infection at the site of block placement

          8. Intolerance or allergy to local anesthetics

          9. Neurologic deficit or disorder

         10. Blood thinning disorder or taking anticoagulant medication

         11. BMI &gt; 50 kg/m2

         12. Suspected or known addiction to or abuse of illicit drug(s), prescription medicine(s),
             or alcohol within the past 2 years

         13. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the
             opinion of the investigator, may interfere with study assessments or compliance

         14. Current or historical evidence of any clinically significant disease or condition
             that, in the opinion of the investigator, may increase the risk of surgery or
             complicate the subject's postoperative course
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Marcus MA, Brodner G. Are opioids contraindicated as postoperative pain relief for patients who are breast-feeding their newborn? Curr Opin Anaesthesiol. 2001 Jun;14(3):287-9.</citation>
    <PMID>17019104</PMID>
  </reference>
  <reference>
    <citation>Marcus H, Gerbershagen HJ, Peelen LM, Aduckathil S, Kappen TH, Kalkman CJ, Meissner W, Stamer UM. Quality of pain treatment after caesarean section: Results of a multicentre cohort study. Eur J Pain. 2015 Aug;19(7):929-39. doi: 10.1002/ejp.619. Epub 2014 Nov 21.</citation>
    <PMID>25413847</PMID>
  </reference>
  <reference>
    <citation>Bateman BT, Cole NM, Maeda A, Burns SM, Houle TT, Huybrechts KF, Clancy CR, Hopp SB, Ecker JL, Ende H, Grewe K, Raposo Corradini B, Schoenfeld RE, Sankar K, Day LJ, Harris L, Booth JL, Flood P, Bauer ME, Tsen LC, Landau R, Leffert LR. Patterns of Opioid Prescription and Use After Cesarean Delivery. Obstet Gynecol. 2017 Jul;130(1):29-35. doi: 10.1097/AOG.0000000000002093.</citation>
    <PMID>28594763</PMID>
  </reference>
  <reference>
    <citation>Osmundson SS, Schornack LA, Grasch JL, Zuckerwise LC, Young JL, Richardson MG. Postdischarge Opioid Use After Cesarean Delivery. Obstet Gynecol. 2017 Jul;130(1):36-41. doi: 10.1097/AOG.0000000000002095.</citation>
    <PMID>28594766</PMID>
  </reference>
  <reference>
    <citation>Bateman BT, Franklin JM, Bykov K, Avorn J, Shrank WH, Brennan TA, Landon JE, Rathmell JP, Huybrechts KF, Fischer MA, Choudhry NK. Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. Am J Obstet Gynecol. 2016 Sep;215(3):353.e1-353.e18. doi: 10.1016/j.ajog.2016.03.016. Epub 2016 Mar 17.</citation>
    <PMID>26996986</PMID>
  </reference>
  <reference>
    <citation>Eslamian L, Jalili Z, Jamal A, Marsoosi V, Movafegh A. Transversus abdominis plane block reduces postoperative pain intensity and analgesic consumption in elective cesarean delivery under general anesthesia. J Anesth. 2012 Jun;26(3):334-8. doi: 10.1007/s00540-012-1336-3. Epub 2012 Feb 22.</citation>
    <PMID>22354671</PMID>
  </reference>
  <reference>
    <citation>Fusco P, Scimia P, Paladini G, Fiorenzi M, Petrucci E, Pozone T, Vacca F, Behr A, Micaglio M, Danelli G, Cofini V, Necozione S, Carta G, Petrini F, Marinangeli F. Transversus abdominis plane block for analgesia after Cesarean delivery. A systematic review. Minerva Anestesiol. 2015 Feb;81(2):195-204. Epub 2014 Apr 16. Review.</citation>
    <PMID>24739207</PMID>
  </reference>
  <reference>
    <citation>Factor D, Chin KJ. Transversus abdominis plane block in lower segment cesarean section: a question of block failure or lack of efficacy? Reg Anesth Pain Med. 2010 Jul-Aug;35(4):404-5. doi: 10.1097/AAP.0b013e3181e66f01.</citation>
    <PMID>20588155</PMID>
  </reference>
  <reference>
    <citation>Loane H, Preston R, Douglas MJ, Massey S, Papsdorf M, Tyler J. A randomized controlled trial comparing intrathecal morphine with transversus abdominis plane block for post-cesarean delivery analgesia. Int J Obstet Anesth. 2012 Apr;21(2):112-8. doi: 10.1016/j.ijoa.2012.02.005. Epub 2012 Mar 10.</citation>
    <PMID>22410586</PMID>
  </reference>
  <reference>
    <citation>Blanco R, Ansari T, Riad W, Shetty N. Quadratus Lumborum Block Versus Transversus Abdominis Plane Block for Postoperative Pain After Cesarean Delivery: A Randomized Controlled Trial. Reg Anesth Pain Med. 2016 Nov/Dec;41(6):757-762. Erratum in: Reg Anesth Pain Med. 2018;43:111.</citation>
    <PMID>27755488</PMID>
  </reference>
  <reference>
    <citation>Kadam VR. Ultrasound guided quadratus lumborum block or posterior transversus abdominis plane block catheter infusion as a postoperative analgesic technique for abdominal surgery. J Anaesthesiol Clin Pharmacol. 2015 Jan-Mar;31(1):130-1. doi: 10.4103/0970-9185.150575.</citation>
    <PMID>25788791</PMID>
  </reference>
  <reference>
    <citation>Kadam VR, Howell S. Ultrasound-guided continuous transmuscular quadratus lumborum block- L4 or L2 level catheter insertion for analgesia in open abdominal surgery: Case series. Indian J Anaesth. 2018 Jul;62(7):555-557. doi: 10.4103/ija.IJA_242_18.</citation>
    <PMID>30078860</PMID>
  </reference>
  <reference>
    <citation>Chin KJ, Malhas L, Perlas A. The Erector Spinae Plane Block Provides Visceral Abdominal Analgesia in Bariatric Surgery: A Report of 3 Cases. Reg Anesth Pain Med. 2017 May/Jun;42(3):372-376. doi: 10.1097/AAP.0000000000000581.</citation>
    <PMID>28272292</PMID>
  </reference>
  <reference>
    <citation>Luis-Navarro JC, Seda-Guzmán M, Luis-Moreno C, Chin KJ. Erector spinae plane block in abdominal surgery: Case series. Indian J Anaesth. 2018 Jul;62(7):549-554. doi: 10.4103/ija.IJA_57_18.</citation>
    <PMID>30078859</PMID>
  </reference>
  <reference>
    <citation>Tulgar S, Selvi O, Kapakli MS. Erector Spinae Plane Block for Different Laparoscopic Abdominal Surgeries: Case Series. Case Rep Anesthesiol. 2018 Feb 18;2018:3947281. doi: 10.1155/2018/3947281. eCollection 2018.</citation>
    <PMID>29670771</PMID>
  </reference>
  <reference>
    <citation>Yamak Altinpulluk E, García Simón D, Fajardo-Pérez M. Erector spinae plane block for analgesia after lower segment caesarean section: Case report. Rev Esp Anestesiol Reanim. 2018 May;65(5):284-286. doi: 10.1016/j.redar.2017.11.006. Epub 2018 Jan 17. English, Spanish.</citation>
    <PMID>29352577</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

